Introduction
Background
Amebiasis is caused by Entamoeba histolytica, a protozoan found worldwide. The highest prevalence of amebiasis is in developing countries where barriers between human feces and food and water supplies are inadequate.
Although most cases of amebiasis are asymptomatic, dysentery and invasive extraintestinal disease can occur. Amebic liver abscess is the most common manifestation of invasive amebiasis, but other organs can also be involved, including pleuropulmonary, cardiac, cerebral, renal, genitourinary, and cutaneous sites. In developed countries, amebiasis primarily affects migrants from and travelers to endemic regions, men who have sex with men, and immunosuppressed or institutionalized individuals.
E histolytica is transmitted via ingestion of the cystic form (infective stage) of the protozoa. Viable in the environment for weeks to months, cysts can be found in fecally contaminated soil, fertilizer, or water or on the contaminated hands of food handlers. Fecal-oral transmission can also occur in the setting of anal sexual practices or direct rectal inoculation through colonic irrigation devices. Excystation then occurs in the terminal ileum or colon, resulting in trophozoites (invasive form). The trophozoites can penetrate and invade the colonic mucosal barrier, leading to tissue destruction, secretory bloody diarrhea, and colitis resembling inflammatory bowel disease. In addition, the trophozoites can spread hematogenously via the portal circulation to the liver or even to more distant organs.
Amebic infection was first described by Fedor Losch in 1875 in St. Petersburg, Russia. In 1890, Sir William Osler reported the first North American case of amebiasis, when he observed amebae in stool and abscess fluid from a physician who previously resided in Panama. The species name E histolytica was first coined by Fritz Schaudin in 1903. In 1913, in the Philippines, Walker and Sellards documented the cyst as the infective form of E histolytica. The life cycle was then established by Dobell in 1925.
Pathophysiology
E histolytica is a pseudopod-forming, nonflagellated protozoal parasite that causes proteolysis and tissue lysis (hence its name) and can induce host-cell apoptosis. Humans and perhaps nonhuman primates are the only natural hosts. Ingestion of E histolytica cysts from the environment is followed by excystation in the terminal ileum or colon to form highly motile trophozoites. Upon colonization of the colonic mucosa, the trophozoite may encyst and is then excreted in the feces or may invade the intestinal mucosal barrier and gain access to the blood stream and disseminate to the liver, lung, and other sites. Excreted cysts reach the environment to complete the cycle.
Disease may be caused by only a small number of cysts, but the processes of encystation and excystation are poorly understood. The adherence of trophozoites to colonic epithelial cells seems to be mediated by a galactose/N -acetylgalactosamine (GAL/GalNAc)–specific lectin.1,2 A mucosal immunoglobulin A (IgA) response against this lectin can result in fewer recurrent infections.3 Both lytic and apoptotic pathways have been described. Cytolysis can be undertaken by amoebapores, a family of peptides capable of forming pores in lipid bilayers.1 Furthermore, in animal models of liver abscess, trophozoites induced apoptosis via a non-Fas and non–tumor necrosis factor-α1 receptor pathway.4 The amoebapores, at sublytic concentrations, can also induce apoptosis.
Cysteine proteinases have been directly implicated in invasion and inflammation of the gut and may amplify interleukin (IL)–1–mediated inflammation by mimicking the action of human IL-1–converting enzyme, cleaving IL-1 precursor to its active form.1,5 The cysteine proteinases can also cleave and inactivate the anaphylatoxins C3a and C5a, as well as IgA and immunoglobulin G (IgG).6,7
Epithelial cells also produce various inflammatory mediators, including IL-1B, IL-8, and cyclooxygenase-2, leading to the attraction of neutrophils and macrophages.8,9 Corticosteroid therapy is known to worsen the clinical outcome, possibly because of its blunting effect on this innate immune response. Additional host defenses, including the complement system, could be inhibited directly by the trophozoites, suggested by the finding that a region of the GAL/GalNAc–specific lectin showed antigenic crossreactivity with CD59, a membrane inhibitor of the C5b-9 attack complex in human red blood cells.10 Trophozoites that reach the liver create unique abscesses with well-circumscribed regions of dead hepatocytes surrounded by few inflammatory cells and trophozoites and unaffected hepatocytes, suggesting that E histolytica are able to kill hepatocytes without direct contact.1
The genus Entamoeba contains many species, some of which (ie, E histolytica, Entamoeba dispar, Entamoeba moshkovskii, Entamoeba polecki, Entamoeba coli, Entamoeba hartmanni) can reside in the human interstitial lumen. E histolytica is, thus far, the only Entamoeba species definitely associated with disease; the others are considered nonpathogenic.11 More recent studies have recovered E dispar and E moshkovskii from patients with gastrointestinal symptoms, but a causal relationship is undetermined.11
E dispar and E histolytica cannot be differentiated by direct examination, but recent molecular techniques established them as two different species, with E dispar being commensal (including in patients with HIV infection) and E histolytica pathogenic.11 In fact, it is now estimated that many individuals with Entamoeba infections are colonized with E dispar, which appears to be 10 times more common than E histolytica.11 However, in certain regions (eg, Brazil, Egypt), asymptomatic E dispar and E histolytica infections are equally prevalent.1 In Western countries, approximately 20%-30% of men who have sex with men are colonized with E dispar.11
Frequency
United States
The overall prevalence of amebiasis is approximately 4%. However, certain groups are predisposed to amebic colitis, including very young patients, pregnant women, recipients of corticosteroids, and malnourished individuals.1 In 1993, a total of 2970 cases of amebiasis were reported to the Centers for Disease Control and Prevention (CDC); 33% of cases were reported in Hispanic immigrants and 17% in immigrants from Asia or the Pacific Islands. Travelers to endemic areas are at risk for infection; 10% of individuals returning with diarrhea were found to have amebiasis.1 Amebic liver abscess has been reported in travel exposures as short as 4 days (median, 3 mo), whereas amebic colitis is uncommon in short-term travelers.
International
Entamoeba species infect approximately 10% of the world's population. The prevalence of Entamoeba infection is as high as 50% in areas of Central and South America, Africa, and Asia. In Egypt, 38% of individuals presenting with acute diarrhea to an outpatient clinic were found to have amebic colitis.1 E histolytica seroprevalence studies in Mexico revealed that more than 8% of the population were positive.12 Asymptomatic E histolytica infections seem to be region-dependent, as high as 11% in Brazil. Since the introduction of molecular techniques, it is estimated that 500 million individuals with Entamoeba infection are colonized by E dispar.11
Mortality/Morbidity
- Amebiasis is second only to malaria in terms of protozoa-associated mortality. The combined prevalence of amebic colitis and amebic liver abscess is estimated at 40-50 million cases annually worldwide, resulting in 40,000-100,000 deaths.11,1,13
- Asymptomatic intestinal amebiasis occurs in 90% of infected individuals. However, only 4%-10% of individuals with asymptomatic amebiasis who were monitored for one year eventually developed colitis or extraintestinal disease.11
- Case fatality rates associated with amebic colitis range from 1.9%-9.1%. Amebic colitis evolves to fulminant necrotizing colitis or rupture in approximately 0.5% of cases; in such cases, the mortality rate jumps to greater than 40%.14
- The mortality rate due to amebic liver abscess has fallen to 1-3% in the last century following the introduction of effective medical treatment. Nevertheless, amebic liver abscess is complicated by sudden intraperitoneal rupture in 2-7% of patients, leading to a higher mortality rate.1
Race
- In Japan and Taiwan, HIV seropositivity is a risk factor for invasive extraintestinal amebiasis.15 This has not been observed elsewhere.
Sex
- Amebic colitis affects both sexes equally.1
- Amebic liver abscess is 7-12 times more common in men than in women, with a predominance among men aged 18-50 years. The reason for this sexual disparity is unknown, although hormonal effects may be implicated, as the prevalence of amebic liver abscess is also increased among postmenopausal women. Alcohol may also been an important risk factor. The sexual distribution is equal in children.1
Age
Very young children seem to be predisposed to fulminant colitis.
Clinical
History
- Amebic colitis
- The most common presentation of amebic colitis is gradual onset of bloody diarrhea, abdominal pain, and tenderness spanning several weeks’ duration.
- Rectal bleeding without diarrhea can occur, especially in children.
- Only approximately 10-30% of patients with amebic colitis develop fever.
- Weight loss and anorexia may occur.
- Fulminant or necrotizing colitis usually manifests as severe bloody diarrhea and widespread abdominal pain with evidence of peritonitis and fever.
- Predisposing factors for fulminant colitis include poor nutrition, pregnancy, corticosteroid use, and very young age.
- Amebic liver abscess
- The most typical presentation of amebic liver abscess is fever, right upper quadrant pain, and tenderness of less than 10 days’ duration.
- Unlike amebic colitis, amebic liver abscess is associated with fever in 85-90% of cases.
- A more subacute presentation can be seen, with concomitant weight loss and anorexia.
- Cough can occur. Jaundice is unusual.
- Acute abdominal symptoms and signs should prompt rapid investigation for intraperitoneal rupture.
- Sixty to 70% of patients with amebic liver abscess do not have concomitant colitis, although a history of dysentery within the previous year may be obtained.
- Amebic liver abscess may manifest years after travel to or residency in an endemic area.
- A history of alcohol abuse is common, but a clear causal relationship is unclear.
- Pleuropulmonary amebiasis: Cough, pleuritic chest pain, and respiratory distress may be clues to rupture through the diaphragm, a rare but serious complication of amebic liver abscess.
- Cerebral amebiasis
- Occurring in 0.6% of amebic liver abscess cases, abrupt onset of nausea, vomiting, headache, and mental status change should prompt rapid investigation for CNS involvement.
- Progression can be very rapid.
Physical
- Amebic colitis
- Fever (10-30%)
- Weight loss (40%)
- Diffuse abdominal tenderness (12-85%)
- Heme-positive stools (70-100%)
- Abdominal pain, distension, and rebound tenderness likely in fulminant colitis
- Amebic liver abscess
- Fever (85-90%)
- Right upper quadrant abdominal tenderness (84-90%)
- Weight loss (33-50%)
- Hepatomegaly (30-50%)
- Jaundice (6-10%)
Causes
- Amebiasis is an infection caused by the protozoal organism E histolytica, which can cause colitis and other extraintestinal manifestations, including liver abscess (most common) and pleuropulmonary, cardiac, and cerebral dissemination.
- E histolytica is transmitted primarily through the fecal-oral route. Infective cysts can be found in fecally contaminated food and water supplies and contaminated hands of food handlers. Sexual transmission is possible, especially in the setting of oral-anal practices.
More on Amebiasis |
Overview: Amebiasis |
| Differential Diagnoses & Workup: Amebiasis |
| Treatment & Medication: Amebiasis |
| Follow-up: Amebiasis |
| Multimedia: Amebiasis |
| References |
| Next Page » |
References
Stanley SL Jr. Amoebiasis. Lancet. Mar 22 2003;361(9362):1025-34. [Medline].
Ravdin JI, Stanley P, Murphy CF, et al. Characterization of cell surface carbohydrate receptors for Entamoeba histolytica adherence lectin. Infect Immun. Jul 1989;57(7):2179-86. [Medline].
Haque R, Mondal D, Duggal P, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun. Feb 2006;74(2):904-9. [Medline].
Seydel KB, Stanley SL Jr. Entamoeba histolytica induces host cell death in amebic liver abscess by a non-Fas-dependent, non-tumor necrosis factor alpha-dependent pathway of apoptosis. Infect Immun. Jun 1998;66(6):2980-3. [Medline].
Que X, Reed SL. Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev. Apr 2000;13(2):196-206. [Medline].
Kelsall BL, Ravdin JI. Degradation of human IgA by Entamoeba histolytica. J Infect Dis. Nov 1993;168(5):1319-22. [Medline].
Reed SL, Keene WE, McKerrow JH, et al. Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica. J Immunol. Jul 1 1989;143(1):189-95. [Medline].
Seydel KB, Li E, Swanson PE, et al. Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun. May 1997;65(5):1631-9. [Medline].
Stenson WF, Zhang Z, Riehl T, et al. Amebic infection in the human colon induces cyclooxygenase-2. Infect Immun. May 2001;69(5):3382-8. [Medline].
Braga LL, Ninomiya H, McCoy JJ, et al. Inhibition of the complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica. J Clin Invest. Sep 1992;90(3):1131-7. [Medline].
Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. Jul 2007;20(3):511-32, table of contents. [Medline].
Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg. Apr 1994;50(4):412-9. [Medline].
Li E, Stanley SL Jr. Protozoa. Amebiasis. Gastroenterol Clin North Am. Sep 1996;25(3):471-92. [Medline].
Aristizábal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg. Mar-Apr 1991;15(2):216-21. [Medline].
Hung CC, Deng HY, Hsiao WH, Hsieh SM, Hsiao CF, Chen MY, et al. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch Intern Med. Feb 28 2005;165(4):409-15. [Medline].
Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol. Mar 28 2006;12(12):1933-6. [Medline].
Bassily S, Farid Z, el-Masry NA, et al. Treatment of intestinal E. histolytica and G. lamblia with metronidazole, tinidazole and ornidazole: a comparative study. J Trop Med Hyg. Feb 1987;90(1):9-12. [Medline].
Gonzalez-Ruiz A, Haque R, Rehman T, et al. Diagnosis of amebic dysentery by detection of Entamoeba histolytica fecal antigen by an invasive strain-specific, monoclonal antibody-based enzyme-linked immunosorbent assay. J Clin Microbiol. Apr 1994;32(4):964-70. [Medline].
Guerrant RL, Brush J, Ravdin JI, et al. Interaction between Entamoeba histolytica and human polymorphonuclear neutrophils. J Infect Dis. Jan 1981;143(1):83-93. [Medline].
Hai AA, Singh A, Mittal VK, et al. Amoebic liver abscess. Review of 220 cases. Int Surg. Apr-Jun 1991;76(2):81-3. [Medline].
Haque R, Ali IK, Akther S, et al. Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. J Clin Microbiol. Feb 1998;36(2):449-52. [Medline].
Haque R, Neville LM, Hahn P, et al. Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J Clin Microbiol. Oct 1995;33(10):2558-61. [Medline].
Kagan IG. Serologic diagnosis of parasitic diseases. N Engl J Med. Mar 19 1970;282(12):685-6. [Medline].
McAuley JB, Herwaldt BL, Stokes SL, et al. Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States. Clin Infect Dis. Sep 1992;15(3):464-8. [Medline].
McAuley JB, Juranek DD. Paromomycin in the treatment of mild-to-moderate intestinal amebiasis. Clin Infect Dis. Sep 1992;15(3):551-2. [Medline].
Petri WA Jr. Recent advances in amebiasis. Crit Rev Clin Lab Sci. Jan 1996;33(1):1-37. [Medline].
Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis. Nov 1999;29(5):1117-25. [Medline].
Petri WA, Singh U, Ravdin JI. Enteric amebiasis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice. Vol 1. Philadelphia, Pa: Churchill Livingstone; 1999:685-97.
Ravdin JI. Amebiasis. Clin Infect Dis. Jun 1995;20(6):1453-64; quiz 1465-6. [Medline].
Ravdin JI, Stauffer WM. Entamoeba histolytica (Amebiasis). In: Mandell: Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, Pa: Churchill Livingstone; 2005:3097-111.
Tachibana H, Kobayashi S, Okuzawa E, et al. Detection of pathogenic Entamoeba histolytica DNA in liver abscess fluid by polymerase chain reaction. Int J Parasitol. Dec 1992;22(8):1193-6. [Medline].
Further Reading
Keywords
amebiasis, amoebiasis, enteric amebiasis, amebic colitis, amebic liver abscess, ALA, amebic hepatic abscess, hepatic amebiasis, pleuropulmonary amebiasis, cerebral amebiasis, invasive amebiasis, cardiac amebiasis, renal amebiasis, genitourinary amebiasis, cutaneous amebiasis, amebic infection, Entamoeba histolytica, E histolytica, amebiosis, Entamoeba dispar, Entamoeba moshkovskii, Entamoeba polecki, Entamoeba coli, Entamoeba hartmanni, E dispar, E moshkovskii, E polecki, E coli, E hartmanni
Overview: Amebiasis